# Risks of Long-term Secondary Malignancies in Breast Cancer Patients Treated with Adjuvant Chemotherapy

See [Jupyter Notebook](metaregSecMal.ipynb) for full details.

## Main results

1. Estimated incidence rate of **AML or MDS** malignancies
    1. By cumulative cyclophophamide dose ([PNG](AMLorMDS_Cyclophosphamide.png))
    1. By cumulative taxane dose ([PNG](AMLorMDS_Taxane.png))
1. Estimated incidence rate of **AML** malignancies
    1. By cumulative cyclophophamide dose ([PNG](AML_Cyclophosphamide.png))
    1. By cumulative taxane dose ([PNG](AML_Taxane.png))
1. Estimated incidence rate of **non-breast solid** malignancies
    1. By cumulative cyclophophamide dose ([PNG](NonBreastSolid_Cyclophosphamide.png))
    1. By cumulative taxane dose ([PNG](NonBreastSolid_Taxane.png))
